Compare Heron Therapeutics Inc (HRTX) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs MakeMyTrip Ltd — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while MakeMyTrip Ltd trades at $44.57 (market cap $4.09B). The key difference: MakeMyTrip Ltd is far larger — about 60.1× Heron Therapeutics Inc's market cap, and Heron Therapeutics Inc is more actively traded (1,891,941 versus 1,828,010). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and MakeMyTrip Ltd for 12 Days on average.
| HRTX | MMYT | |
|---|---|---|
Market Cap | $68.01M | $4.09B |
Volume | 1,891,941 | 1,828,010 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $94.43 |
52-Week Low | $0.27 | $36.30 |
Typical Hold Time | 35 Days | 12 Days |
Enterprise Value | $174.75M | $4.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.4061, up 4.13% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics (-22.52% net margin), analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX faces significant fundamental challenges with consistent losses and negative ROE, though revenue stability provides some foundation. The strong analyst support suggests potential upside if operational improvements materialize, but high execution risk and cash flow concerns warrant caution for investors seeking near-term profitability.
MMYT trades at $44.73, up 3.04% today, but technical indicators signal a bearish trend with support at $42. The stock shows mixed earnings, missing Q4 2025 and Q2 2026 estimates but beating Q1 2026. Revenue grew to $978.34M in 2025, though net income margin is thin at 3.23%. Analyst consensus is strongly bullish with a $77 price target, but cash flow turned negative in 2026, and debt-to-asset ratio surged, raising financial stability concerns.
The outlook is bifurcated: strong analyst support and a high target suggest upside, but deteriorating cash flow, rising leverage, and bearish technicals pose significant risks. Investors should weigh the potential from operational resilience and a planned Indian listing against financial volatility and macroeconomic pressures on travel demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
